Total trials

139

Active

3

Phase 3

36

Total enrollment

22,863

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
CYB7041
Ocrevus-EU1
Ocrevus-US1
GME7512
Keytruda - EU1
Keytruda - US1

Next readouts

  • 2026-06
  • 2026-11

Top conditions

  • Depression13
  • Healthy11
  • HIV Infections10
  • Hypertension8
  • Cytopenias6
  • Rheumatoid Arthritis6
  • Anemia5
  • Breast Cancer4

Frequently asked questions about Sandoz

How many clinical trials does Sandoz have on ClinicalTrials.gov?
Sandoz is listed as the lead sponsor on 139 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
How many of Sandoz's trials are in Phase 3?
36 of Sandoz's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Sandoz focus on?
Sandoz's most-studied conditions on ClinicalTrials.gov are Depression, Healthy, HIV Infections, Hypertension, Cytopenias.
When are Sandoz's next clinical trial readouts?
Sandoz has 2 upcoming primary-completion readouts tracked here; the soonest is “A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma”, expected around 2026-06.